It has also been shown that the non-metabolism function of EGFR activates PKM2 in β-catenin transactivation and subsequent cell proliferation and tumorigenesis in GBM, prostate and breast cancer cell lines [43, 44]. Here, PKM is linked to breast carcinoma.